| __timestamp | Celldex Therapeutics, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 8901000 |
| Thursday, January 1, 2015 | 4011000 | 9574000 |
| Friday, January 1, 2016 | 102026000 | 14695000 |
| Sunday, January 1, 2017 | 96171000 | 8437000 |
| Monday, January 1, 2018 | 66449000 | 12723000 |
| Tuesday, January 1, 2019 | 42672000 | 51272000 |
| Wednesday, January 1, 2020 | 42534000 | 50052000 |
| Friday, January 1, 2021 | 3068000 | 783000 |
| Saturday, January 1, 2022 | 1400000 | 868000 |
| Sunday, January 1, 2023 | 3008000 | 123740000 |
Cracking the code
In the ever-evolving world of biotechnology, understanding financial health is crucial. This analysis delves into the cost of revenue trends for Geron Corporation and Celldex Therapeutics, Inc. over the past decade. From 2014 to 2023, Celldex Therapeutics experienced a dramatic 98% decrease in cost of revenue, from a peak of $102 million in 2016 to just $3 million in 2023. In contrast, Geron Corporation's cost of revenue fluctuated, peaking at $124 million in 2023, a staggering 1,300% increase from its 2014 figures. These trends highlight the volatile nature of the biotech industry, where strategic shifts and market dynamics can significantly impact financial outcomes. As investors and stakeholders navigate this landscape, understanding these financial patterns is key to making informed decisions.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: GSK plc vs Geron Corporation
Takeda Pharmaceutical Company Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Geron Corporation
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Vericel Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Geron Corporation vs Travere Therapeutics, Inc.
Geron Corporation or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.